The potent effect of BAY1082439 in inhibiting cancer cell-intrinsic immunosuppressive activity prompted us to test whether BAY1082439 treatment could turn Pten-null prostate cancer to T cell-inflamed and promote T cell-mediated anti-tumor immunity in vivo. The gene discussed is PTEN; the disease is prostate cancer.